Literature DB >> 18085232

Clinical pharmacology and use of microtubule-targeting agents in cancer therapy.

Amelia B Zelnak1.   

Abstract

The microtubule-targeting agents have made significant contributions to cancer therapy over the past 50 years. The vinca alkaloids and taxanes have been used to treat a broad range of malignancies, including leukemias and lymphomas and many types of solid tumors. The taxanes have been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and they are increasingly being used in early stage disease. This chapter reviews the pharmacology, clinical indications, and toxicities associated with the vinca alkaloids and taxanes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18085232     DOI: 10.1007/978-1-59745-442-1_15

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  8 in total

1.  Anaphase catastrophe is a target for cancer therapy.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Saranya Ravi; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2011-02-02       Impact factor: 12.531

Review 2.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

3.  Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Authors:  Elizabeth A Hopper-Borge; Timothy Churchill; Chelsy Paulose; Emmanuelle Nicolas; Joely D Jacobs; Olivia Ngo; Yehong Kuang; Alex Grinberg; Heiner Westphal; Zhe-Sheng Chen; Andres J Klein-Szanto; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

4.  PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells.

Authors:  E N Maginn; P V Browne; P Hayden; E Vandenberghe; B MacDonagh; P Evans; M Goodyer; P Tewari; G Campiani; S Butini; D C Williams; D M Zisterer; M P Lawler; A M McElligott
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

5.  TaxKB: a knowledge base for new taxane-related drug discovery.

Authors:  Kasi Murugan; Sangeetha Shanmugasamy; Saleh Al-Sohaibani; Naga Vignesh; Kandavel Palanikannan; Antonydhason Vimala; Gopal Ramesh Kumar
Journal:  BioData Min       Date:  2015-06-28       Impact factor: 2.522

6.  Hepatoma upregulated protein expression is involved in the pathogenesis of human breast carcinogenesis.

Authors:  Jin Chen; Qiu-Jun Liu; DA Wang; Xian-Yao Zhou; Ding Xiong; Hong-Jiang Li; Chang-Long Li
Journal:  Oncol Lett       Date:  2014-10-13       Impact factor: 2.967

7.  PPARgamma Inhibitors as Novel Tubulin-Targeting Agents.

Authors:  Katherine L Schaefer
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

8.  SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers.

Authors:  Shun Matsuura; Tomoaki Kahyo; Kazuya Shinmura; Moriya Iwaizumi; Hidetaka Yamada; Kazuhito Funai; Jun Kobayashi; Masayuki Tanahashi; Hiroshi Niwa; Hiroshi Ogawa; Takashi Takahashi; Naoki Inui; Takafumi Suda; Kingo Chida; Yoshinori Watanabe; Haruhiko Sugimura
Journal:  Sci Rep       Date:  2013-10-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.